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ORIGINAL ARTICLE
Benzodiazepine use in medical out-patient clinics: a study from a developing
country
Muhammad Junaid Patel,1 Syed Ahmer,2 Faheem Khan,3 Abdullah Waqar Ahmed Qureshi,4
Muhammad Farrukh Shehzad,5 Sania Muzaffar6

Abstract
Objective: To estimate the prevalence of Benzodiazepine use in the outpatient setting of general medicine clinics
at a single tertiary care centre.
Methods: The prospective prevalence study was conducted in the outpatient setting of Internal Medicine Clinics at
Aga Khan University Hospital, Karachi, from November to December 2009. All subjects were interviewed after
informed consent and variables were recorded on a specially-designed proforma. Apart from basic demographics
and comorbid conditions, duration, frequency and route of benzodiazepine use, as well as the reason and who
initiated it was noted. Chi-square test and t test was applied to see the association of socio demographic or clinical
factors with the use of benzodiazepine.
Results: Of the 355 patients, 129 (36.33%) reported using the drug. The majority (n=86; 24.2%) were taking it on a
daily basis. The highest numbers of patients using the drug were suffering from cardiovascular problems, 32 (25%)
followed by 22 (17%) from endocrinology. Diazepam equivalent dose was around 7.04±4, with a inter-quartile range
of 3-96 weeks. Alprazolam (9%) was the most frequently prescribed Benzodiazepine.
Conclusion: Benzodiazepine use is alarmingly high in the outpatient clinics of General Internal Medicine
Department. There is no implementation of law to prevent its hazardous sale. In this regard all concerned should
work collectively for awareness and irrational drug sale and use.
Keywords: Benzodiazepine, Medical out-patient, Prevalence, Dependence, Drug use, Pakistan. (JPMA 63: 717; 2013)

Introduction
Anxiety and insomnia are common clinical presentations
for centuries. Efforts have been made by healers of each
era to lower human sufferings regarding these ailments.
This quest has led to different classes of medications that
surfaced in recent times such as bromides in 1920,
followed by Barbiturates in 1940. Benzodiazepine (BDZ)
was a major breakthrough in the form of
Chlordiazepoxide in 1957. It gained popularity as higher
doses were not as toxic as its predecessors. This became
the selling point, but in the late 1970s and early 1980s
attention was focussed towards iatrogenic effects of BDZ,
i.e. dependence.1
In the fifth decade of its use, BDZ is still the widely and
most frequently prescribed drug. Prevalence estimates
from National Epidemiologic Survey on Alcohol and
related conditions in USA suggest 0.16 % and 0.13 % of
sedative and tranquiliser use respectively in 2001-02.1 In
Canada, frequency of hypnotic and similar sedative
hypnotic use was found around 3.4%.2 Women and less
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educated people were using it more. In France and Italy,
BDZ use came around 7.5% and 8.6% respectively.2,3
Comparing estimates of US and Canada with European
countries like France gives one some clue to establish a
global picture.
In in-patient setting, BDZs are frequently prescribed but
without proper documentation.4 This is why taking the
scenario of pharmacy system or point prevalence would
give a clue towards the specialty as reported in a study5
which looked into prescription rates of BDZ among
different specialties and reported neurology as the
highest prescribing specialty (35.8%) followed by
orthopaedics (26%).5 A similar study from Pakistan
reported point prevalence of 21% of BDZ use in admitted
patients.6 It also reported surgical specialties using it
more as compared to non-surgical specialties and shortacting Midazolam as the most commonly used one.
Another cross-sectional survey estimated the prevalence
of BDZ use around 30% in patients visiting out-patients
clinic of different specialties.7
Long-term use of BDZ leads to dependence. Dependence
has been estimated by different studies, that came as high
as 45% after six months of continuous use.1,2 This significant
adverse effect profile raised the concern amongst the
medical community. It then led to the development of
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guidelines to restrict its use for pre-anaesthesia, alcohol
detoxification and short-term use for anxiety disorders.8
Despite these measures, BDZs are regarded as one of the
most prescribed class of medications.9
The Drug Abuse Warning Network (DAWN) reported an
increasing trend in the abuse of BDZ (38%) from 1995 to
2002. In this survey, Alprazolam (Xanax®) was reported to be
the highest (62%).10 A recent study from Pakistan also
revealed BDZ overdose (41%) as the most common method
of deliberate self-harm in women more than men.11
A study from Pakistan pointed towards the prevalence of
BDZ use in out-patient psychiatric clinics in two major cities
of Pakistan (Karachi and Lahore) giving alarming results of
45%.12 Psychiatric disorders were estimated around 15-20%
in people presenting with organic disorders.13,14 Medically
un-explained symptoms constitute about one-third of all
patients presenting to doctors. These become a part of
larger group of illness, underlying stress, anxiety and
depression that responds to treatment.15 General
Physicians (GPs) may feel overwhelmed on such
psychological issues and see BDZ as the "lesser evil" in
terms of consolidating doctor-patient relationship.16
It was thought of high interest and value to see BDZ use in
Internal Medicine clinic. We did not come across any study
examining this before from Pakistan.
The objective of the study was to assess period prevalence
and patterns of BDZ use in out-patients of Internal Medicine
practice at a tertiary care centre in Karachi, Pakistan.

Subjects and Methods
The prospective prevalence study was conducted in the
outpatient clinics of Internal Medicine at the Aga Khan
University Hospital (AKUH), in Karachi, Pakistan. Ethical
approval was obtained prior to the study. All patients of
age above 18 who visited the clinic from November to
December 2009 were interviewed. Mentally challenged
and seriously ill patients were excluded.
The questionnaire/proforma was developed initially by
experts after group discussion and also has been used
previously in a study.12 The survey was conducted by
Medical Final Year students voluntarily. Before data
collection all volunteers were trained for it. The data was
collected till the sample size requirement was met. The
proforma encompassed relevant demographic details like
age, gender and level of education etc. The patients were
asked regarding BDZ use, reason to start, duration,
frequency, dosage, type and route of BDZ use. They were
enquired about who prescribed it whether it be a GP,
psychiatrist, self-medicated etc. All co-morbid illnesses
were noted. Diazepam-equivalent doses were calculated
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using Maudslaey Prescribing guidelines.17
Taking estimated prevalence of BDZ use as 30.4% at a
tertiary care hospital as found in literature,7 and taking
precision of 5%, a minimum of 323 subjects were
required, at 0.05 level of significance and 80% power. We
took a total of 355 patients.
SPSS 16.0 was used for data analysis. Chi-square test was
used to analyse categorical variables like city, gender,
whether seen by physician or psychiatrist before, etc.; and ttest to analyse continuous variables like age. Use of BDZ was
taken as dependent variable and other variables that were
statistically significant (p <0.05) as independent variables.

Results
The mean age of the 355 patients was 45±17 years. Interquartile range was 32-60 years. Of the total, 185(52%)
were males; 268(75%) were married; and 87(24%) were
single or widowed. Housewives formed the largest group
116(33%) followed by professionals 74(21%), students
44(12%) and retirees 42(11%). Majority of them (n=134;
38%) were graduates (Table). Patients who presented to
the clinic for medical evaluation were mostly suffering
from both cardiovascular (CVS) 92(26%) and infectious
disease etiology 92(26%) followed by endocrine-related
problems 82(23%), gastrointestinal diseases 57(16%),
musculoskeletal problems 46(13%), Central Nervous
System (CNS) diseases 32(9%) and pulmonology 25(7%)
problems, whereas genitourinary 11(3%) and
haematology 01(0.3%) related illnesses were the least
reported (Figure).
A total of 129(36%) patients reported current use of BDZ.
Of these, 58(45%) continued the use of BDZ on their own
as compared to 30(23%) of the cases where it was

CVS: Cardiovascular system. ENDO: Endocrinology. I/D: Infectious diseases.
M/S: Musculoskeletal. CNS: Central nervous system. PULMO: Pulmonology.
GI: Gastrointestinal. GU: Genitourinary. HAEM: Haematology.

Figure: Period prevalence of benzodiazepine use by medical diagnosis.
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Table: Association between socio-demographic and clinical variables and likelihood of
taking benzodiazepine.

Alprazolam (n=22; 17%), Bromazepam (n=15; 12%),
Lorazepam (n=5; 4%) and Midazolam (n=3; 2%).

Variables

Discussion

Number (%)

Gender (n=355)
Male
185(52)
Female
170(47)
TOTAL
355
Marital Status(n=355)
Married
268(75.4)
Single/widowed
87(24.5)
TOTAL
355(100)
Education
Primary and below
73(20.5)
Secondary
55(15)
Intermediate
80(22.5)
Graduate
134(38)
Postgraduate
13(4)
TOTAL
355(100)
Occupation
Professional
74(21)
Labour
45(13)
Businessman
33(9)
Student
44(12)
Housewife
116(37)
Retired
42(12)
Unemployed
1(0.2)
Total
355(100)

Taking Benzodiazepine (%) P-value
<0.169
61(47)
68(53)
129(100)
<0.002
101(78)
28(22)
129(100)
<0.005
38(29)
20(15)
17(13)
51(39)
3(2)
129(100)
<0.001
25(19
15(12)
11(8)
4(3
51(39)
23(18)
0(0)
129(100)

prescribed persistently by GPs or internists. There was no
gender difference in the prevalence of BDZ use. Among
the single and widows 28 (22%) were on BDZ compared
to 101(78) of the married. Housewives reported using BDZ
in 51(39%) cases, becoming the largest group, followed by
23(18%) of the retired persons, labour 15(12%),
professionals 25(19%) and 11(8%) business-persons. Use
of BDZ was the highest in people having primary
education or less 38(29%) and graduates 51(38%).
Disease-specific description of BDZ use pointed out some
interesting results as 32 (25%) patients suffering from CVS
problems were using BDZ, followed by 23(18%) in
endocrinology, 22(17%) in infectious diseases , 20(15%) in
musculoskeletal, 15(12%) in CNS problems, 6(5%) in
pulmonology, 8(6%) gastrointestinal, 3(2.3%) in
genitourinary and 1(0.7%) in haematology. Among
psychiatric illnesses, generalized anxiety disorder was the
only diagnosis reported by 6(5%).
Among the users, majority (n=31; 24%) were using BDZ
on a daily bases and reported insomnia and anxiety as
reasons for its use. Diazepam-equivalent dose was
calculated to be around 7.04±4, and mean duration of use
was 93.07±203 weeks, with a inter-quartile range of 3-96
weeks. Frequency of particular BDZ being taken was
Vol. 63, No. 6, June 2013

There is paucity of data from this part of the world
regarding the use of BDZ in an outpatient setting of
General Internal Medicine clinics. The current study
reports point prevalence estimates of BDZ use in this
group as well as give important demographic and
relevant clinical correlates.
Prevalence of BDZ usage in our population came around
36%, which can be compared with 21% in the in-patient
setting at the same institute but without discrimination of
any specific specialty.6 In a study done in all out-patient
clinics of the same hospital gave a lifetime prevalence of
BDZ at around 30%.7
A study done at psychiatry out-patient reported 45%
point prevalence of BDZ use in Pakistan.13 Psychiatrists are
primarily responsible for prescribing and managing
anxiety and insomnia issues, but our data gave a new
angle, as in 85(23%) cases it was started by an internist or
a GP compared to the psychiatrists who started it in only
20(6%) cases. Self medication in our study population
came alarmingly high at 58(16%). In Pakistan there are no
strict laws to restrict the selling of BDZ as a prescription
medication only. This may be the reason behind selfprescribers being the highest in number. Greater
prescription rate by an internist may also be
understandable from the phenomena reported in a
qualitative study that GPs take BDZ as the lesser evil
["people do not die by BDZ"].17
In gender-wise description, BDZ usage was almost equally
prevalent in females (68%) and males (61%). This finding is
different from previous studies.13 Housewives as the
second largest group of BDZ users is significant because
in one previous study reported that depressed
housewives were at greater risk of self-harm, giving an
alarming picture and also reporting that BDZ was the
most commonly used option. Among the users, the
majority were married, which is in contrast to high
prevalence in separated and divorce population findings
by one study.18 This may be correlated with distress
associated with the institution of marriage in Pakistan.
Primary education and no education both have high
prevalence of BDZ use.
Majority of the cases presented with symptoms related to
infectious diseases, whereas CNS diseases were low. In
system-specific description, people presented with CVSrelated illnesses were the highest in taking BDZ, followed
by Endocrine problems, infections-related problems and
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musculoskeletal problems. The results can be compared
with a study in Japan, where they focussed on in-patient
pattern of BDZ prescription, giving Neurology as the
highest in prescribing (35.8%), followed by cardiac
surgery (35.8%), orthopedics (26.3%), general surgery
(24.1%) and internal medicine (23.7%).10 As our study was
conducted in Medicine clinics, it was likely to have less
cases related to surgical problems. High BDZ use in
patients suffering from CVS problems may also be
explained over Pakistan-specific prescription trend as
here GP/Internist prescribes BDZ for the control of
hypertension.19
Alprazolam was used the most, followed by Bromazepam,
Lorazepam and Midazolam, while the rest were in much
lower numbers. Differences from previous two studies at
the same institution explain that in psychiatric outpatient, Clonazepam (longer duration) was the highest
and in all in-patients it was Midazolam (shortest
acting).6,13 This is understandable as psychiatrists
prescribed BDZ for anxiety and insomnia primarily
compared to the Internist and surgical team for anxiety
and surgical procedures.
In terms of limitations, the study was conducted at a
private-sector hospital where patients have to pay from
their pocket, thus limiting easy access of patients. The
study sample, as such, may not be the true representative
of the general population. Secondly, as this study is based
on self-reporting patients, it carries a risk of underreporting, which also limits it generalisibility. A sample
size of 355 patients is not enough to elicit significant
aspects of this important issue and we believe that a
larger sample size is needed for more relevant results.

Conclusion
BDZ use was found to be alarmingly high. Despite
established high risk of dependence associated with BDZ
use, they were prescribed randomly. Self-medication
trend also was an eye opener, reflecting the need to
increase awareness among all stakeholders. Retirees and
housewives as major groups were flagged, pointing a
need to develop some drug monitoring system.
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